title: [Chronic lymphocytic leukemia. 2. Therapy].
authors.affiliation: Medizinische Klinik III, Ludwig-Maximilians-Universität München, Grosshadern.
authors.forename: M
authors.initials: M
authors.lastname: Hallek
authors.forename: B
authors.initials: B
authors.lastname: Schmitt
authors.forename: B
authors.initials: B
authors.lastname: Emmerich
authors.forename: H
authors.initials: H
authors.lastname: Stein
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002699:Chlorambucil / Q000009:adverse effects / Q000627:therapeutic use; D004307:Dose-Response Relationship, Radiation; D004359:Drug Therapy, Combination; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007116:Immunization, Passive; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D012307:Risk Factors; D013156:Splenectomy; D013256:Steroids / Q000009:adverse effects / Q000627:therapeutic use; D014182:Transplantation, Autologous; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D013256:Steroids; D002699:Chlorambucil; D014740:Vidarabine; C024352:fludarabine